Results 181 to 190 of about 17,658 (223)
Some of the next articles are maybe not open access.
Bulletin du Cancer, 2015
Resume Le paclitaxel est classiquement utilise dans un vaste eventail d’indications en oncologie. Le nab-paclitaxel est synthetise par un processus d’homogeneisation a haute pression du paclitaxel en presence d’albumine humaine et il a ete initialement developpe pour diminuer la toxicite generalement associee au cremophor du paclitaxel soluble et ...
Daniel Lopez-Trabada Ataz +2 more
openaire +1 more source
Resume Le paclitaxel est classiquement utilise dans un vaste eventail d’indications en oncologie. Le nab-paclitaxel est synthetise par un processus d’homogeneisation a haute pression du paclitaxel en presence d’albumine humaine et il a ete initialement developpe pour diminuer la toxicite generalement associee au cremophor du paclitaxel soluble et ...
Daniel Lopez-Trabada Ataz +2 more
openaire +1 more source
Nab-paclitaxel in patients with metastatic melanoma
Expert Review of Anticancer Therapy, 2015Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic ...
Roberto A, Leon-Ferre +1 more
openaire +2 more sources
Cystoid macular edema induced by nab-paclitaxel
Breast Cancer, 2012Cystoid macular edema (CME) is a rare complication of taxane-based chemotherapy. We encountered a patient who developed CME during treatment with nab-paclitaxel for metastatic breast cancer. Early detection of this disease enables continuation of appropriate treatment without reducing the quality of life for patients with end-stage disease.
Yuko, Tanaka +4 more
openaire +2 more sources
Metabolism of the taxanes including nab-paclitaxel
Expert Opinion on Drug Metabolism & Toxicology, 2014The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most widely used anticancer drugs. Despite years of research, the optimal dosing regimen (weekly vs 3-weekly) and optimal dose is still controversial, as is the value of pharmacological personalization of taxane dosing ...
openaire +3 more sources
nab-Paclitaxel mechanisms of action and delivery
Journal of Controlled Release, 2013Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and severe toxicities.
openaire +2 more sources
Bulletin du cancer, 2015
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Efficacy of nab-paclitaxel in treating metastatic melanoma
Expert Opinion on Pharmacotherapy, 2019Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical ...
openaire +3 more sources
Gemcitabine/nab‐paclitaxel for pediatric relapsed/refractory sarcomas
Pediatric Blood & Cancer, 2018AbstractBackgroundPediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab‐paclitaxel in combination has not been reported in pediatrics.ProcedureWe reviewed the records of fifteen ...
Jonathan L. Metts +7 more
openaire +2 more sources
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
The Kobe journal of medical sciences, 2017Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the compatibility and stability of solutions containing nab-paclitaxel and other drugs, including ...
Mizuta, Naomi +8 more
openaire +2 more sources
nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
Clinical Breast Cancer, 2014Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others.
openaire +2 more sources